

# UOB Investment Insights

## FX Insights


14 February 2022

### A Resilient Singapore Dollar

- SGD has a strong start to 2022 after surprise MAS move
- USD expected to strengthen against SGD as Fed begins aggressive rate hike cycle in March
- Overall, we expect USD/SGD at 1.37 by end-2022

The Singapore dollar (SGD) has held up well against a strengthening US dollar (USD). Year to date, the SGD has gained about 0.4% against the USD at 1.3440 while most of its other Asian peers have slipped. The resilience of the local dollar is partly due to the surprise off-cycle tightening by the Monetary Authority of Singapore (MAS) in late January. In order to combat rising inflation, the MAS has increased the rate of appreciation of the Singapore dollar nominal effective exchange rate (S\$NEER) to an estimated 1% per annum from 0.5% previously. We expect a further increase to 1.5% at the next scheduled policy meeting in April.

That said, the backdrop remains that of a stronger USD as the US Federal Reserve (Fed) is on the cusp of an aggressive rate hike cycle. We expect the Fed to hike 150 basis points (bps) this year, starting with a lift-off in March. While tightening from the MAS will help buffer against some of the depreciation pressures on the SGD, USD/SGD is likely to trade higher. Overall, we expect the currency pair to end 2022 at the 1.37 level.



Source: Bloomberg. Data as at 31 January 2022.



## RIGHT BY YOU

### **IMPORTANT NOTICE AND DISCLAIMERS:**

The information contained in this publication is given on a general basis without obligation and is strictly for information purposes only. This publication is not intended to be, and should not be regarded as, an offer, recommendation, solicitation or advice to buy or sell any investment or insurance product and shall not be transmitted, disclosed, copied or relied upon by any person for whatever purpose. Any description of investment or insurance products, if any, is qualified in its entirety by the terms and conditions of the investment or insurance product and if applicable, the prospectus or constituting document of the investment or insurance product. Nothing in this publication constitutes accounting, legal, regulatory, tax, financial or other advice. If in doubt, you should consult your own professional advisers about issues discussed herein.

The information contained in this publication, including any data, projections and underlying assumptions, are based on certain assumptions, management forecasts and analysis of known information and reflects prevailing conditions as of the date of the publication, all of which are subject to change at any time without notice. Although every reasonable care has been taken to ensure the accuracy and objectivity of the information contained in this publication, United Overseas Bank Limited ("UOB") and its employees make no representation or warranty of any kind, express, implied or statutory, and shall not be responsible or liable for its completeness or accuracy. As such, UOB and its employees accept no liability for any error, inaccuracy, omission or any consequence or any loss/damage howsoever suffered by any person, arising from any reliance by any person on the views expressed or information contained in this publication.

Any opinions, projections and other forward looking statements contained in this publication regarding future events or performance of, including but not limited to, countries, markets or companies are not necessarily indicative of, and may differ from actual events or results. The information herein has no regard to the specific objectives, financial situation and particular needs of any specific person. Investors may wish to seek advice from an independent financial advisor before investing in any investment or insurance product. Should you choose not to seek such advice, you should consider whether the investment or insurance product in question is suitable for you.